Russia approves 2nd coronavirus vaccine after early trials

Russian authorities have given regulatory approval to a second coronavirus vaccine after early-stage studies, two months after a similar move prompted widespread criticism from scientists both at home and abroad.

The peptide-based, two-shot vaccine, EpiVacCorona, was developed by the Vector Institute in Siberia and tested among 100 volunteers in early-stage, placebo-controlled human trials, which lasted more than two months and were completed two weeks ago. The volunteers were between 18 and 60 years old.

The scientists have yet to publish the results of the study. In comments to the media, scientists developing the vaccine said that it produced enough antibodies to protect the person who had it from the virus and that the immunity it creates could last for up to six months. – The Hindu

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.